Cytek Biosciences vs Ginkgo Bioworks
Cytek Biosciences reported revenue of $202 million in fiscal 2025, 1.2 times Ginkgo Bioworks' $170 million in fiscal 2025. Cytek Biosciences' revenue grew 0.5% in its latest year, and Ginkgo Bioworks' fell 25.1%. Cytek Biosciences had an operating margin of -20.0%, against -185.3% at Ginkgo Bioworks. Free cash flow was −$9 million at Cytek Biosciences and −$179 million at Ginkgo Bioworks.
Side by side
| Cytek Biosciences | Ginkgo Bioworks | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $202M | $170M |
| Revenue growth | 0.5% | −25.1% |
| Revenue growth a year, last 5 years | 210.3% | 17.3% |
| Gross margin | 51.8% | — |
| Operating margin | −20.0% | −185.3% |
| Net margin | −33.0% | −183.8% |
| Free cash flow | −$9M | −$179M |
| Free cash flow margin | −4.3% | −105.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $15M | $0M |
| Change in diluted share count | −2.2% | 6.9% |
| Last close | $5.84 | $9.61 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cytek BiosciencesGinkgo Bioworks
Operating margin
Percent of revenue
Cytek BiosciencesGinkgo Bioworks
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cytek BiosciencesGinkgo Bioworks
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cytek Biosciences and Ginkgo Bioworks pages.